S.-H. Kim et al. / Bioorg. Med. Chem. Lett. 18 (2008) 634–639
639
12. Das, J.; Liu, C.; Moquin, R.; Lin, J.; Furch, J. A.; Spergel,
S. H.; McIntyre, K. W.; Shuster, D. J.; O’Day, K. D.;
Penhallow, B.; Hung, C.-H.; Kanner, S. B.; Lin, T.-A.;
Dodd, J. H.; Barrish, J. C.; Wityak, J. Biog. Med. Chem.
Lett. 2006, 16, 2411.
evaluation of these compounds in in vivo models will
be reported in due course.
References and notes
13. Das, J.; Furch, J. A.; Liu, C.; Moquin, R.; Lin, J.; Spergel,
S. H.; McIntyre, K. W.; Shuster, D. J.; O’Day, K. D.;
Penhallow, B.; Hung, C.-H.; Doweyko, A. M.; Kamath,
A.; Zhang, H.; Marathe, P.; Kanner, S. B.; Lin, T.-A.;
Dodd, J. H.; Barrish, J. C.; Wityak, J. Biog. Med. Chem.
Lett. 2006, 16, 3706.
14. Values are means of three experiments with stan-
dard deviation of less than 15%. Assay conditions:
ATP concentration at 10 lM, reaction time = 35 min,
enzyme concentration (lg/well) = 0.008, Substrate
concentration (lg/well) = 0.625 at 30 °C.
15. Till, J. H.; Becerra, M.; Watty, A.; Lu, Y.; Ma, Y.;
Neubert, T. A.; Burden, S. J.; Hubbard, S. R. Structure
2002, 10, 1187.
16. Schrodinger, L. L. C. 32nd Floor, Tower 45, 120 West
Forty-Fifth Street, New York, 10036, 2003.
17. Tokarski, J. S.; Newitt, J. A.; Chang, C. Y. J.; Cheng, J.
D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y.
F.; Borzilleri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.;
Klei, H. E. Cancer Res. 2006, 66, 5790.
1. Nakagawara, A. Cancer Lett. 2001, 169, 107.
2. Huang, E. J.; Reichardt, L. F. Annu. Rev. Biochem. 2003,
72, 609.
3. Schramm, A.; Shulte, J. H.; Astrahantseff, K.; Apostolov,
O.; Limpt, V.; Sieverts, H.; Kuhfittig-Kulle, S.; Pfeiffer, P.;
Versteeg, R.; Eggert, A. Cancer Lett. 2005, 228, 143.
4. Florenes, V. A.; Malanddsmo, G. M.; Holm, R.; Reich,
R.; Lazarovici, P.; Davidson, B. Am. J. Clin. Pathol. 2004,
122, 412.
5. Davidson, B.; Reich, R.; Lazarovici, P.; Nesland, J. M.;
Skered, M.; Risberg, B.; Trope, C. G.; Florenes, V. A.
Clin. Cancer Res. 2003, 9, 2248.
6. Zhang, Y.; Dang, C.; Ma, Q.; Shimahara, Y. Oncol.
Reports 2005, 14, 161.
7. Ruggeri, B. A.; Miknyoczki, S. J.; Singh, J.; Hudkins, R.
L. Curr. Med. Chem. 1999, 6, 845.
8. George, D. J.; Dionne, C. A.; Jani, J.; Angeles, T.;
Murakata, C.; Lamb, J.; Issacs, J. T. Cancer Res. 1999, 59,
2395.
18. RK3E vector (pcDNA3.1, V3.1) or CD8-TrkA trans-
fectants and SH-SY-5Y cells were cultured in
DMEM + 10% FBS or RPMI1640 + 10% FBS, respec-
tively. Confluency after 3 days: 80% for CD8-TrkA and
V3.1cell lines; 65% for SH-SY5Y. All cells were plated
in media containing 2.5% FBS (SH-SY-5Y) or 10%
FBS (RK3E transfectants) and compounds administered
the next day. After 3 days treatment, the cells were
pulsed with 10 ll of diluted {3H}-thymidine at 4 lCi/ml
for 3 h. Values are means of three experiments.
9. Undevia, S. D.; Vogelzang, N. J.; Mauer, A. M.; Janisch,
L.; Mani, S.; Ratain, M. J. Invest. New Drugs 2004, 22,
449.
10. Wood, E. R.; Kuyper, L.; Petrov, K. G.; Hunter, R. N.,
III; Harris, P. A.; Lackey, K. Biorg. Med. Chem. Lett
2004, 14, 953.
11. Lippa, B.; Morris, J.; Corbett, M.; Kwan, T. A.; Noe, M.
C.; Snow, S. L.; Gant, T. G.; Mangiaracina, M.; Coffey,
H. A.; Foster, B.; Knauth, E. A.; Wessel, M. D. Biorg.
Med. Chem. Lett. 2006, 16, 3444.